We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months.
- Authors
Yao, Zhenzhen; Gu, Bin; Chen, Jia; Xu, Yang; Chen, Feng; Xue, Shengli; Qiu, Huiying; Tang, Xiaowen; Han, Yue; Chen, Suning; Sun, Aining; Yu, Lei; Zhang, Yanming; Wu, Depei; Wang, Ying
- Abstract
It is of great interest whether early incorporation of CAR T-cell therapy into frontline treatment could benefit patients. As disease burden is an important parameter for the outcome of CAR T-cell therapy, the scenario in patients with MRD may be different from that in patients with r/r ALL. Blinatumomab is approved for the treatment of MRD-positive Ph negative B-ALL patients since 2018, but not yet for Ph+ ALL patients. One patient achieved remission after CD19/CD22 dual-antigen CAR T-cell therapy and is alive at the last follow-up.
- Subjects
CD19 antigen; CHIMERIC antigen receptors; LYMPHOBLASTIC leukemia; ACUTE leukemia; T cells
- Publication
Blood Cancer Journal, 2023, Vol 13, Issue 1, p1
- ISSN
2044-5385
- Publication type
Article
- DOI
10.1038/s41408-023-00848-0